Skip to Main Content

WASHINGTON — The Centers for Medicare and Medicaid Services laid out a bevy of initiatives Monday that officials said would reduce drug prices for patients covered by the Medicare Part D prescription drug program — but they have made no decisions yet on an issue that has confounded lawmakers and patients alike.

That issue is whether the discounts that pharmacy benefit managers negotiate for drugs — the “rebates” that lawmakers have been raising questions about in recent months — as well as other fees, should go toward lowering the price that a patient pays at the pharmacy.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED
  • Right now if the companies would change their stand on private and government insurance we would have better medicare prices right now. If on Medicare don’t bother asking for a break from the companies it’s only for people who can afford their products.

Comments are closed.